Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T + CAR-NK (The Second Hospital of Shandong University)
- Development stage
- Unknown
- Lead developer
- Second Hospital of Shandong University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy is a combination of chimeric antigen receptor T (CAR-T) cells and chimeric antigen receptor natural killer (CAR-NK) cells developed by The Second Hospital of Shandong University. The therapy is designed to treat recurrent, refractory, or unresectable solid tumors, including pancreatic cancer, prostate cancer, breast cancer, and glioma. By combining CAR-T and CAR-NK cells, the treatment aims to leverage the potent, long-term effector functions of T cells alongside the rapid response and potentially lower toxicity profile of NK cells. Research from the developing institution indicates that these cells are engineered to target antigens commonly expressed in solid tumors, such as mesothelin (MSLN) and B7-H3 (CD276), to overcome the immunosuppressive microenvironment and improve therapeutic efficacy in non-hematologic malignancies.
- Other names
- CAR-T/CAR-NK cell injectionCAR-T/CAR-NK cells
02
Targets
B7-H3Mesothelin
Beyond the preview
Go deeper on CAR-T + CAR-NK (The Second Hospital of Shandong University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T + CAR-NK (The Second Hospital of Shandong University).